

7. Literaturverzeichnis

1. Jacobson, M.D., M. Weil, and M.C. Raff. 1997. Programmed cell death in animal development. *Cell*. 88:347-54.
2. Ellis, R.E., J.Y. Yuan, and H.R. Horvitz. 1991. Mechanisms and functions of cell death. *Annu Rev Cell Biol*. 7:663-98.
3. Kerr, J.F., A.H. Wyllie, and A.R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer*. 26:239-57.
4. Thompson, C.B. 1995. Apoptosis in the pathogenesis and treatment of disease. *Science*. 267:1456-62.
5. Nicholson, D.W. 1996. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. *Nat Biotechnol*. 14:297-301.
6. Yuan, J., S. Shaham, S. Ledoux, H.M. Ellis, and H.R. Horvitz. 1993. The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. *Cell*. 75:641-52.
7. Miura, M., H. Zhu, R. Rotello, E.A. Hartwig, and J. Yuan. 1993. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the *C. elegans* cell death gene *ced-3*. *Cell*. 75:653-60.
8. Alnemri, E.S., D.J. Livingston, D.W. Nicholson, G. Salvesen, N.A. Thornberry, W.W. Wong, and J. Yuan. 1996. Human ICE/CED-3 protease nomenclature. *Cell*. 87:171.
9. Martin, S.J., and D.R. Green. 1995. Protease activation during apoptosis: death by a thousand cuts? *Cell*. 82:349-52.
10. Thornberry, N.A., H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner, J. Aunins, and et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. *Nature*. 356:768-74.
11. Walker, N.P., R.V. Talanian, K.D. Brady, L.C. Dang, N.J. Bump, C.R. Ferez, S. Franklin, T. Ghayur, M.C. Hackett, L.D. Hammill, and et al. 1994. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)₂ homodimer. *Cell*. 78:343-52.
12. Yang, X., H.Y. Chang, and D. Baltimore. 1998. Autoproteolytic activation of pro-caspases by oligomerization. *Mol Cell*. 1:319-25.
13. Cohen, G.M. 1997. Caspases: the executioners of apoptosis. *Biochem J*. 326:1-16.

14. Boldin, M.P., E.E. Varfolomeev, Z. Pancer, I.L. Mett, J.H. Camonis, and D. Wallach. 1995. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. *J Biol Chem.* 270:7795-8.
15. Chinnaiyan, A.M., K. O'Rourke, M. Tewari, and V.M. Dixit. 1995. Yama/ CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. *Cell.* 81:505-512.
16. Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. Rodman, J. Salfeld, and et al. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. *Cell.* 80:401-11.
17. Wang, S., M. Miura, Y.K. Jung, H. Zhu, E. Li, and J. Yuan. 1998. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. *Cell.* 92:501-9.
18. Kang, S.J., S. Wang, H. Hara, E.P. Peterson, S. Namura, S. Amin-Hanjani, Z. Huang, A. Srinivasan, K.J. Tomaselli, N.A. Thornberry, M.A. Moskowitz, and J. Yuan. 2000. Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. *J Cell Biol.* 149:613-22.
19. Hu, S., S.J. Snipas, C. Vincenz, G. Salvesen, and V.M. Dixit. 1998. Caspase-14 is a novel developmentally regulated protease. *J Biol Chem.* 273:29648-53.
20. Ahmad, M., S.M. Srinivasula, R. Hegde, R. Mukattash, T. Fernandes-Alnemri, and E.S. Alnemri. 1998. Identification and characterization of murine caspase-14, a new member of the caspase family. *Cancer Res.* 58:5201-5.
21. Kamada, S., M. Washida, J. Hasegawa, H. Kusano, Y. Funahashi, and Y. Tsujimoto. 1997. Involvement of caspase-4(-like) protease in Fas-mediated apoptotic pathway. *Oncogene.* 15:285-90.
22. Humke, E.W., J. Ni, and V.M. Dixit. 1998. ERICE, a novel FLICE-activatable caspase. *J Biol Chem.* 273:15702-7.
23. Kuida, K., T.S. Zheng, S. Na, C. Kuan, D. Yang, H. Karasuyama, P. Rakic, and R.A. Flavell. 1996. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. *Nature.* 384:368-72.
24. Woo, M., R. Hakem, M.S. Soengas, G.S. Duncan, A. Shahinian, D. Kagi, A. Hakem, M. McCurrach, W. Khoo, S.A. Kaufman, G. Senaldi, T. Howard, S.W. Lowe, and T.W. Mak. 1998. Essential contribution of caspase 3/ CPP32 to apoptosis and its associated nuclear changes. *Genes Dev.* 12:806-19.

25. Hakem, R., A. Hakem, G.S. Duncan, J.T. Henderson, M. Woo, M.S. Soengas, A. Elia, J.L. de la Pompa, D. Kagi, W. Khoo, J. Potter, R. Yoshida, S.A. Kaufman, S.W. Lowe, J.M. Penninger, and T.W. Mak. 1998. Differential requirement for caspase 9 in apoptotic pathways in vivo. *Cell*. 94:339-52.
26. Varfolomeev, E.E., M. Schuchmann, V. Luria, N. Chiannilkulchai, J.S. Beckmann, I.L. Mett, D. Rebrikov, V.M. Brodianski, O.C. Kemper, O. Kollet, T. Lapidot, D. Soffer, T. Sobe, K.B. Avraham, T. Goncharov, H. Holtmann, P. Lonai, and D. Wallach. 1998. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. *Immunity*. 9:267-76.
27. Juo, P., C.J. Kuo, J. Yuan, and J. Blenis. 1998. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. *Curr Biol*. 8:1001-8.
28. Blanc, C., Q.L. Deveraux, S. Krajewski, R.U. Janicke, A.G. Porter, J.C. Reed, R. Jaggi, and A. Marti. 2000. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. *Cancer Res*. 60:4386-90.
29. Enari, M., H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, and S. Nagata. 1998. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature*. 391:43-50.
30. Earnshaw, W.C., L.M. Martins, and S.H. Kaufmann. 1999. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. *Annu Rev Biochem*. 68:383-424.
31. Mitamura, S., H. Ikawa, N. Mizuno, Y. Kaziro, and H. Itoh. 1998. Cytosolic nuclease activated by caspase-3 and inhibited by DFF-45. *Biochem Biophys Res Commun*. 243:480-4.
32. Tang, D., and V.J. Kidd. 1998. Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis. *J Biol Chem*. 273:28549-52.
33. Essmann, F., T. Wieder, A. Otto, E.C. Muller, B. Dorken, and P.T. Daniel. 2000. GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. *Biochem J*. 346 Pt 3:777-83.
34. Slee, E.A., C. Adrain, and S.J. Martin. 2000. Executioner caspases-3, -6 and -7 perform distinct, non-redundant, roles during the demolition phase of apoptosis. *J Biol Chem*.
35. Daniel, P.T. 2000. Dissecting the pathways to death. *Leukemia*. 14:2035-44.
36. Burns, T.F., and W.S. El-Deiry. 1999. The p53 pathway and apoptosis. *J Cell Physiol*. 181:231-9.

37. Nakagawa, T., H. Zhu, N. Morishima, E. Li, J. Xu, B.A. Yankner, and J. Yuan. 2000. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. *Nature*. 403:98-103.
38. Newmeyer, D.D., D.M. Farschon, and J.C. Reed. 1994. Cell-free apoptosis in *Xenopus* egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. *Cell*. 79:353-64.
39. Li, P., D. Nijhawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S. Alnemri, and X. Wang. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. *Cell*. 91:479-489.
40. Cecconi, F. 1999. Apaf1 and the apoptotic machinery. *Cell Death Differ*. 6:1087-98.
41. Slee, E.A., M.T. Harte, R.M. Kluck, B.B. Wolf, C.A. Casiano, D.D. Newmeyer, H.G. Wang, J.C. Reed, D.W. Nicholson, E.S. Alnemri, D.R. Green, and S.J. Martin. 1999. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. *J Cell Biol*. 144:281-92.
42. Purring-Koch, C., and G. McLendon. 2000. Cytochrome c binding to apaf-1: the effects of dATP and ionic strength. *Proc Natl Acad Sci U S A*. 97:11928-31.
43. Saleh, A., S.M. Srinivasula, S. Acharya, R. Fishel, and E.S. Alnemri. 1999. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. *J Biol Chem*. 274:17941-5.
44. Zou, H., Y. Li, X. Liu, and X. Wang. 1999. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. *J Biol Chem*. 274:11549-56.
45. Susin, S.A., H.K. Lorenzo, N. Zamzami, I. Marzo, B.E. Snow, G.M. Brothers, J. Mangion, E. Jacotot, P. Costantini, M. Loeffler, N. Larochette, D.R. Goodlett, R. Aebersold, D.P. Siderovski, J.M. Penninger, and G. Kroemer. 1999. Molecular characterization of mitochondrial apoptosis-inducing factor. *Nature*. 397:441-6.
46. Daugas, E., D. Nochy, L. Ravagnan, M. Loeffler, S.A. Susin, N. Zamzami, and G. Kroemer. 2000. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. *FEBS Lett*. 476:118-23.
47. Krajewski, S., M. Krajewska, L.M. Ellerby, K. Welsch, Z. Xie, Q.L. Deveraux, G.S. Salvesen, D.E. Bredesen, R.E. Rosenthal, G. Fiskum, and J.C. Reed. 1999. Release of Caspase-9 from Mitochondria During Neuronal Apoptosis and Cerebral Ischemia. *Submitted*.

48. Zhivotovsky, B., A. Samali, A. Gahm, and S. Orrenius. 1999. Caspases: their intracellular localization and translocation during apoptosis. *Cell Death Differ.* 6:644-51.
49. Verhagen, A.M., P.G. Ekert, M. Pakusch, J. Silke, L.M. Connolly, G.E. Reid, R.L. Moritz, R.J. Simpson, and D.L. Vaux. 2000. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell.* 102:43-53.
50. Du, C., M. Fang, Y. Li, L. Li, and X. Wang. 2000. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell.* 102:33-42.
51. Green, D.R., and J.C. Reed. 1998. Mitochondria and apoptosis. *Science.* 281:1309-12.
52. Fiers, W., R. Beyaert, W. Declercq, and P. Vandenabeele. 1999. More than one way to die: apoptosis, necrosis and reactive oxygen damage. *Oncogene.* 18:7719-30.
53. Degli Esposti, M., and H. McLennan. 1998. Mitochondria and cells produce reactive oxygen species in virtual anaerobiosis: relevance to ceramide-induced apoptosis. *FEBS Lett.* 430:338-42.
54. Jacobson, M.D., and M.C. Raff. 1995. Programmed cell death and Bcl-2 protection in very low oxygen. *Nature.* 374:814-6.
55. Tsujimoto, Y., J. Gorham, J. Cossman, E. Jaffe, and C.M. Croce. 1985. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. *Science.* 229:1390-3.
56. Tsujimoto, Y. 1989. Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. *Oncogene.* 4:1331-6.
57. Vaux, D.L., S. Cory, and J.M. Adams. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature.* 335:440-2.
58. Adams, J.M., and S. Cory. 1998. The Bcl-2 protein family: arbiters of cell survival. *Science.* 281:1322-6.
59. Reed, J.C. 1998. Bcl-2 family proteins. *Oncogene.* 17:3225-36.
60. Holinger, E.P., T. Chittenden, and R.J. Lutz. 1999. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. *J Biol Chem.* 274:13298-304.
61. Kelekar, A., B.S. Chang, J.E. Harlan, S.W. Fesik, and C.B. Thompson. 1997. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. *Mol Cell Biol.* 17:7040-6.

62. Sattler, M., H. Liang, D. Nettesheim, R.P. Meadows, J.E. Harlan, M. Eberstadt, H.S. Yoon, S.B. Shuker, B.S. Chang, A.J. Minn, C.B. Thompson, and S.W. Fesik. 1997. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. *Science*. 275:983-6.
63. Wang, K., A. Gross, G. Waksman, and S.J. Korsmeyer. 1998. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. *Mol Cell Biol*. 18:6083-9.
64. Chittenden, T., C. Flemington, A.B. Houghton, R.G. Ebb, G.J. Gallo, B. Elangovan, G. Chinnadurai, and R.J. Lutz. 1995. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. *Embo J*. 14:5589-96.
65. Simonen, M., H. Keller, and J. Heim. 1997. The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis. *Eur J Biochem*. 249:85-91.
66. Minn, A.J., P. Velez, S.L. Schendel, H. Liang, S.W. Muchmore, S.W. Fesik, M. Fill, and C.B. Thompson. 1997. Bcl-x(L) forms an ion channel in synthetic lipid membranes. *Nature*. 385:353-7.
67. Schlesinger, P.H., A. Gross, X.M. Yin, K. Yamamoto, M. Saito, G. Waksman, and S.J. Korsmeyer. 1997. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. *Proc Natl Acad Sci U S A*. 94:11357-62.
68. Schendel, S.L., Z. Xie, M.O. Montal, S. Matsuyama, M. Montal, and J.C. Reed. 1997. Channel formation by antiapoptotic protein Bcl-2. *Proc Natl Acad Sci U S A*. 94:5113-8.
69. Antonsson, B., S. Montessuit, S. Lauper, R. Eskes, and J.C. Martinou. 2000. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. *Biochem J*. 345 Pt 2:271-8.
70. Desagher, S., and J.C. Martinou. 2000. Mitochondria as the central control point of apoptosis. *Trends Cell Biol*. 10:369-77.
71. Priault, M., B. Chaudhuri, A. Clow, N. Camougrand, and S. Manon. 1999. Investigation of bax-induced release of cytochrome c from yeast mitochondria permeability of mitochondrial membranes, role of VDAC and ATP requirement. *Eur J Biochem*. 260:684-91.
72. Eskes, R., B. Antonsson, A. Osen-Sand, S. Montessuit, C. Richter, R. Sadoul, G. Mazzei, A. Nichols, and J.C. Martinou. 1998. Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg²⁺ ions. *J Cell Biol*. 143:217-24.

-
73. Crompton, M. 1999. The mitochondrial permeability transition pore and its role in cell death. *Biochem J.* 341:233-49.
 74. Jurgensmeier, J.M., Z. Xie, Q. Deveraux, L. Ellerby, D. Bredesen, and J.C. Reed. 1998. Bax directly induces release of cytochrome c from isolated mitochondria. *Proc Natl Acad Sci U S A.* 95:4997-5002.
 75. Narita, M., S. Shimizu, T. Ito, T. Chittenden, R.J. Lutz, H. Matsuda, and Y. Tsujimoto. 1998. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. *Proc Natl Acad Sci U S A.* 95:14681-6.
 76. Shimizu, S., M. Narita, and Y. Tsujimoto. 1999. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. *Nature.* 399:483-7.
 77. Marzo, I., C. Brenner, N. Zamzami, J.M. Jurgensmeier, S.A. Susin, H.L. Vieira, M.C. Prevost, Z. Xie, S. Matsuyama, J.C. Reed, and G. Kroemer. 1998. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. *Science.* 281:2027-31.
 78. Shimizu, S., and Y. Tsujimoto. 2000. Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity. *Proc Natl Acad Sci U S A.* 97:577-82.
 79. Goldstein, J.C., N.J. Waterhouse, P. Juin, G.I. Evan, and D.R. Green. 2000. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. *Nat Cell Biol.* 2:156-62.
 80. Gross, A., K. Pilcher, E. Blachly-Dyson, E. Basso, J. Jockel, M.C. Bassik, S.J. Korsmeyer, and M. Forte. 2000. Biochemical and genetic analysis of the mitochondrial response of yeast to BAX and BCL-X(L). *Mol Cell Biol.* 20:3125-36.
 81. Puthalakath, H., D.C. Huang, L.A. O'Reilly, S.M. King, and A. Strasser. 1999. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. *Mol Cell.* 3:287-96.
 82. Pastorino, J.G., M. Tafani, and J.L. Farber. 1999. Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway. *J Biol Chem.* 274:19411-6.

83. Harada, H., B. Becknell, M. Wilm, M. Mann, L.J. Huang, S.S. Taylor, J.D. Scott, and S.J. Korsmeyer. 1999. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. *Mol Cell*. 3:413-22.
84. Hu, Y., M.A. Benedict, D. Wu, N. Inohara, and G. Nunez. 1998. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. *Proc Natl Acad Sci U S A*. 95:4386-91.
85. Newmeyer, D.D., E. Bossy-Wetzel, R.M. Kluck, B.B. Wolf, H.M. Beere, and D.R. Green. 2000. Bcl-xL does not inhibit the function of Apaf-1. *Cell Death Differ*. 7:402-7.
86. Hausmann, G., L.A. O'Reilly, R. van Driel, J.G. Beaumont, A. Strasser, J.M. Adams, and D.C. Huang. 2000. Pro-apoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x(L). *J Cell Biol*. 149:623-34.
87. Inohara, N., T.S. Gourley, R. Carrio, M. Muniz, J. Merino, I. Garcia, T. Koseki, Y. Hu, S. Chen, and G. Nunez. 1998. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. *J Biol Chem*. 273:32479-86.
88. Beutler, B., and C. van Huffel. 1994. Unraveling function in the TNF ligand and receptor families. *Science*. 264:667-8.
89. Magnusson, C., and D.L. Vaux. 1999. Signalling by CD95 and TNF receptors: not only life and death. *Immunol Cell Biol*. 77:41-6.
90. Banner, D.W., A. D'Arcy, W. Janes, R. Gentz, H.J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell*. 73:431-45.
91. Tartaglia, L.A., T.M. Ayres, G.H. Wong, and D.V. Goeddel. 1993. A novel domain within the 55 kd TNF receptor signals cell death. *Cell*. 74:845-53.
92. Smith, C.A., H.J. Gruss, T. Davis, D. Anderson, T. Farrah, E. Baker, G.R. Sutherland, C.I. Brannan, N.G. Copeland, N.A. Jenkins, and et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. *Cell*. 73:1349-60.
93. Ashkenazi, A., and V.M. Dixit. 1998. Death receptors: signaling and modulation. *Science*. 281:1305-8.
94. Cohen, P.L., and R.A. Eisenberg. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. *Annu Rev Immunol*. 9:243-69.

95. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. *Cell*. 76:969-76.
96. Muzio, M., B.R. Stockwell, H.R. Stennicke, G.S. Salvesen, and V.M. Dixit. 1998. An induced proximity model for caspase-8 activation. *J Biol Chem*. 273:2926-30.
97. Nunez, G., M.A. Benedict, Y. Hu, and N. Inohara. 1998. Caspases: the proteases of the apoptotic pathway. *Oncogene*. 17:3237-3245.
98. Yang, X., R. Khosravi-Far, H.Y. Chang, and D. Baltimore. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. *Cell*. 89:1067-76.
99. Takeda, K., T. Hatai, T.S. Hamazaki, H. Nishitoh, M. Saitoh, and H. Ichijo. 2000. Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells. *J Biol Chem*. 275:9805-13.
100. Zhong, S., P. Salomoni, S. Ronchetti, A. Guo, D. Ruggero, and P.P. Pandolfi. 2000. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. *J Exp Med*. 191:631-40.
101. Hennino, A., M. Berard, M. Casamayor-Palleja, P.H. Krammer, and T. Defrance. 2000. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. *J Immunol*. 165:3023-30.
102. Pitti, R.M., S.A. Marsters, D.A. Lawrence, M. Roy, F.C. Kischkel, P. Dowd, A. Huang, C.J. Donahue, S.W. Sherwood, D.T. Baldwin, P.J. Godowski, W.I. Wood, A.L. Gurney, K.J. Hillan, R.L. Cohen, A.D. Goddard, D. Botstein, and A. Ashkenazi. 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. *Nature*. 396:699-703.
103. Tartaglia, L.A., and D.V. Goeddel. 1992. Two TNF receptors. *Immunol Today*. 13:151-3.
104. White, D.W., and J.T. Harty. 1998. Perforin-deficient CD8+ T cells provide immunity to *Listeria monocytogenes* by a mechanism that is independent of CD95 and IFN-gamma but requires TNF-alpha. *J Immunol*. 160:898-905.
105. Baker, S.J., and E.P. Reddy. 1998. Modulation of life and death by the TNF receptor superfamily. *Oncogene*. 17:3261-70.
106. Hsu, H., H.B. Shu, M.G. Pan, and D.V. Goeddel. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. *Cell*. 84:299-308.

107. Chinnaiyan, A.M., C.G. Tepper, M.F. Seldin, K. O'Rourke, F.C. Kischkel, S. Hellbardt, P.H. Krammer, M.E. Peter, and V.M. Dixit. 1996. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. *J Biol Chem.* 271:4961-5.
108. Declercq, W., G. Denecker, W. Fiers, and P. Vandenabeele. 1998. Cooperation of both TNF receptors in inducing apoptosis: involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. *J Immunol.* 161:390-9.
109. Duan, H., and V.M. Dixit. 1997. RAIDD is a new 'death' adaptor molecule. *Nature.* 385:86-9.
110. Zhang, J., D. Cado, A. Chen, N.H. Kabra, and A. Winoto. 1998. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. *Nature.* 392:296-300.
111. Yeh, W.C., J.L. Pompa, M.E. McCurrach, H.B. Shu, A.J. Elia, A. Shahinian, M. Ng, A. Wakeham, W. Khoo, K. Mitchell, W.S. El-Deiry, S.W. Lowe, D.V. Goeddel, and T.W. Mak. 1998. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. *Science.* 279:1954-8.
112. Newton, K., A.W. Harris, M.L. Bath, K.G.C. Smith, and A. Strasser. 1998. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. *Embo J.* 17:706-18.
113. Pan, G., J. Ni, Y.F. Wei, G. Yu, R. Gentz, and V.M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science.* 277:815-8.
114. Pan, G., J.H. Bauer, V. Haridas, S. Wang, D. Liu, G. Yu, C. Vincenz, B.B. Aggarwal, J. Ni, and V.M. Dixit. 1998. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. *FEBS Lett.* 431:351-6.
115. Ashkenazi, A., and V.M. Dixit. 1999. Apoptosis control by death and decoy receptors. *Curr Opin Cell Biol.* 11:255-60.
116. Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell.* 94:481-90.
117. Li, H., H. Zhu, C.J. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell.* 94:491-501.
118. Perez, D., and E. White. 2000. TNF-alpha signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. *Mol Cell.* 6:53-63.

119. Zamzami, N., C. El Hamel, C. Maise, C. Brenner, C. Munoz-Pinedo, A.S. Belzacq, P. Costantini, H. Vieira, M. Loeffler, G. Molle, and G. Kroemer. 2000. Bid acts on the permeability transition pore complex to induce apoptosis. *Oncogene*. 19:6342-50.
120. Kaufmann, S.H. 1998. Cell death induced by topoisomerase-targeted drugs: more questions than answers. *Biochim Biophys Acta*. 1400:195-211.
121. Wang, J.C. 1985. DNA topoisomerases. *Annu Rev Biochem*. 54:665-97.
122. Berger, J.M., S.J. Gamblin, S.C. Harrison, and J.C. Wang. 1996. Structure and mechanism of DNA topoisomerase II. *Nature*. 379:225-32.
123. Burden, D.A., P.S. Kingma, S.J. Froelich-Ammon, M.A. Bjornsti, M.W. Patchan, R.B. Thompson, and N. Osheroff. 1996. Topoisomerase II. etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. *J Biol Chem*. 271:29238-44.
124. Zhang, H., P. D'Arpa, and L.F. Liu. 1990. A model for tumor cell killing by topoisomerase poisons. *Cancer Cells*. 2:23-7.
125. Osheroff, N. 1989. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. *Biochemistry*. 28:6157-60.
126. Chan, E.M., M.J. Thomas, B. Bandy, and G.F. Tibbits. 1996. Effects of doxorubicin, 4'-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes. *Can J Physiol Pharmacol*. 74:904-10.
127. Grankvist, K., U. Stendahl, and R. Henriksson. 1989. Comparative study of demethoxydaunorubicin with other anthracyclines on generation of oxygen radicals and clonogenic survival of fibroblasts. *Pharmacol Toxicol*. 65:40-4.
128. Hannun, Y.A. 1996. Functions of ceramide in coordinating cellular responses to stress. *Science*. 274:1855-9.
129. Obeid, L.M., C.M. Linares, L.A. Karolak, and Y.A. Hannun. 1993. Programmed cell death induced by ceramide. *Science*. 259:1769-71.
130. Tepper, C.G., S. Jayadev, B. Liu, A. Bielawska, R. Wolff, S. Yonehara, Y.A. Hannun, and M.F. Seldin. 1995. Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. *Proc Natl Acad Sci U S A*. 92:8443-7.
131. Bettaieb, A., I. Plo, V. Mansat-De Mas, A. Quillet-Mary, T. Levade, G. Laurent, and J.P. Jaffrezou. 1999. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis. *Mol Pharmacol*. 55:118-25.

132. Haimovitz-Friedman, A., C.C. Kan, D. Ehleiter, R.S. Persaud, M. McLoughlin, Z. Fuks, and R.N. Kolesnick. 1994. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. *Journal of Experimental Medicine*. 180:525-535.
133. Hannun, Y.A., and C. Luberto. 2000. Ceramide in the eukaryotic stress response. *Trends Cell Biol.* 10:73-80.
134. Yoshimura, S., Y. Banno, S. Nakashima, K. Takenaka, H. Sakai, Y. Nishimura, N. Sakai, S. Shimizu, Y. Eguchi, Y. Tsujimoto, and Y. Nozawa. 1998. Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bcl-2 on ceramide formation and caspase-3 activation. *Journal of Biological Chemistry*. 273:6921-6927.
135. Dbaibo, G.S., D.K. Perry, C.J. Gamard, R. Platt, G.G. Poirier, L.M. Obeid, and Y.A. Hannun. 1997. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. *J Exp Med*. 185:481-90.
136. Susin, S.A., N. Zamzami, M. Castedo, E. Daugas, H.G. Wang, S. Geley, F. Fassy, J.C. Reed, and G. Kroemer. 1997. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. *J Exp Med*. 186:25-37.
137. Lee, J.Y., Y.A. Hannun, and L.M. Obeid. 1996. Ceramide inactivates cellular protein kinase Calpha. *J Biol Chem*. 271:13169-74.
138. Santana, P., L.A. Pena, A. Haimovitz-Friedman, S. Martin, D. Green, M. McLoughlin, C. Cordon-Cardo, E.H. Schuchman, Z. Fuks, and R. Kolesnick. 1996. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. *Cell*. 86:189-99.
139. Lozano, J., S. Menendez, A. Morales, D. Ehleiter, W.C. Liao, R. Wagman, A. Haimovitz-Friedman, Z. Fuks, and R. Kolesnick. 2001. Cell Autonomous Apoptosis Defects in Acid Sphingomyelinase Knockout Fibroblasts. *J Biol Chem*. 276:442-448.
140. Kolesnick, R.N., and M. Kronke. 1998. Regulation of ceramide production and apoptosis. *Annu Rev Physiol*. 60:643-65.
141. Adam-Klages, S., D. Adam, K. Wiegmann, S. Struve, W. Kolanus, J. Schneider-Mergener, and M. Kronke. 1996. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. *Cell*. 86:937-47.

-
142. Adam, D., K. Wiegmann, S. Adam-Klages, A. Ruff, and M. Kronke. 1996. A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway. *J Biol Chem.* 271:14617-22.
143. Schwandner, R., K. Wiegmann, K. Bernardo, D. Kreder, and M. Kronke. 1998. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. *J Biol Chem.* 273:5916-22.
144. Nickels, J.T., and J.R. Broach. 1996. A ceramide-activated protein phosphatase mediates ceramide-induced G1 arrest of *Saccharomyces cerevisiae*. *Genes Dev.* 10:382-94.
145. Wolff, R.A., R.T. Dobrowsky, A. Bielawska, L.M. Obeid, and Y.A. Hannun. 1994. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. *J Biol Chem.* 269:19605-9.
146. Galadari, S., K. Kishikawa, C. Kamibayashi, M.C. Mumby, and Y.A. Hannun. 1998. Purification and characterization of ceramide-activated protein phosphatases. *Biochemistry.* 37:11232-8.
147. Kishikawa, K., C.E. Chalfant, D.K. Perry, A. Bielawska, and Y.A. Hannun. 1999. Phosphatidic acid is a potent and selective inhibitor of protein phosphatase 1 and an inhibitor of ceramide-mediated responses. *J Biol Chem.* 274:21335-41.
148. Ruvolo, P.P., X. Deng, T. Ito, B.K. Carr, and W.S. May. 1999. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. *J Biol Chem.* 274:20296-300.
149. Ito, A., T. Uehara, A. Tokumitsu, Y. Okuma, and Y. Nomura. 1999. Possible involvement of cytochrome c release and sequential activation of caspases in ceramide-induced apoptosis in SK-N-MC cells. *Biochim Biophys Acta.* 1452:263-74.
150. Zhang, Y., B. Yao, S. Delikat, S. Bayoumy, X.H. Lin, S. Basu, M. McGinley, P.Y. Chan-Hui, H. Lichenstein, and R. Kolesnick. 1997. Kinase suppressor of Ras is ceramide-activated protein kinase. *Cell.* 89:63-72.
151. Paris, F., H. Grassme, A. Cremesti, J. Zager, Y. Fong, A. Haimovitz-Friedman, Z. Fuks, E. Gulbins, and R. Kolesnick. 2000. Natural ceramide reverses Fas resistance of acid sphingomyelinase^{super-/-} hepatocytes. *J Biol Chem.*
152. Sawada, M., S. Nakashima, Y. Banno, H. Yamakawa, K. Hayashi, K. Takenaka, Y. Nishimura, N. Sakai, and Y. Nozawa. 2000. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. *Cell Death Differ.* 7:761-72.

153. Barkett, M., and T.D. Gilmore. 1999. Control of apoptosis by Rel/NF-kappaB transcription factors. *Oncogene*. 18:6910-24.
154. Chen, F.E., and G. Ghosh. 1999. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. *Oncogene*. 18:6845-52.
155. Gilmore, T.D. 1999. The Rel/NF-kappaB signal transduction pathway: introduction. *Oncogene*. 18:6842-4.
156. Inoue, J., L.D. Kerr, L.J. Ransone, E. Bengal, T. Hunter, and I.M. Verma. 1991. c-rel activates but v-rel suppresses transcription from kappa B sites. *Proc Natl Acad Sci U S A*. 88:3715-9.
157. Henkel, T., T. Machleidt, I. Alkalay, M. Kronke, Y. Ben-Neriah, and P.A. Baeuerle. 1993. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. *Nature*. 365:182-5.
158. Miyamoto, S., M. Maki, M.J. Schmitt, M. Hatanaka, and I.M. Verma. 1994. Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. *Proc Natl Acad Sci U S A*. 91:12740-4.
159. Naumann, M., and C. Scheidereit. 1994. Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. *Embo J*. 13:4597-607.
160. Mellits, K.H., R.T. Hay, and S. Goodbourn. 1993. Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. *Nucleic Acids Res*. 21:5059-66.
161. Zandi, E., and M. Karin. 1999. Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. *Mol Cell Biol*. 19:4547-51.
162. May, M.J., and S. Ghosh. 1999. IkappaB kinases: kinsmen with different crafts. *Science*. 284:271-3.
163. Tsao, D.H., T. McDonagh, J.B. Telliez, S. Hsu, K. Malakian, G.Y. Xu, and L.L. Lin. 2000. Solution structure of N-TRADD and characterization of the interaction of N-TRADD and C-TRAF2, a key step in the TNFR1 signaling pathway. *Mol Cell*. 5:1051-7.
164. Rothe, M., S.C. Wong, W.J. Henzel, and D.V. Goeddel. 1994. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. *Cell*. 78:681-92.
165. Yeh, W.C., A. Shahinian, D. Speiser, J. Kraunus, F. Billia, A. Wakeham, J.L. de la Pompa, D. Ferrick, B. Hum, N. Iscove, P. Ohashi, M. Rothe, D.V. Goeddel, and T.W.

- Mak. 1997. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. *Immunity*. 7:715-25.
166. Kelliher, M.A., S. Grimm, Y. Ishida, F. Kuo, B.Z. Stanger, and P. Leder. 1998. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. *Immunity*. 8:297-303.
167. Koseki, T., N. Inohara, S. Chen, R. Carrio, J. Merino, M.O. Hottiger, G.J. Nabel, and G. Nunez. 1999. CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10. *J Biol Chem*. 274:9955-61.
168. Srinivasula, S.M., M. Ahmad, J.H. Lin, J.L. Poyet, T. Fernandes-Alnemri, P.N. Tsichlis, and E.S. Alnemri. 1999. CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis. *J Biol Chem*. 274:17946-54.
169. Ozes, O.N., L.D. Mayo, J.A. Gustin, S.R. Pfeffer, L.M. Pfeffer, and D.B. Donner. 1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature*. 401:82-5.
170. Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene*. 18:6853-66.
171. Jiang, Y., J.D. Woronicz, W. Liu, and D.V. Goeddel. 1999. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. *Science*. 283:543-6.
172. Liou, M.L., and H.C. Liou. 1999. The ubiquitin-homology protein, DAP-1, associates with tumor necrosis factor receptor (p60) death domain and induces apoptosis. *J Biol Chem*. 274:10145-53.
173. De Valck, D., D.Y. Jin, K. Heyninck, M. Van de Craen, R. Contreras, W. Fiers, K.T. Jeang, and R. Beyaert. 1999. The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases. *Oncogene*. 18:4182-90.
174. Lee, E.G., D.L. Boone, S. Chai, S.L. Libby, M. Chien, J.P. Lodolce, and A. Ma. 2000. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. *Science*. 289:2350-4.
175. Sen, R., and D. Baltimore. 1986. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. *Cell*. 47:921-8.
176. Pasparakis, M., L. Alexopoulou, M. Grell, K. Pfizenmaier, H. Bluethmann, and G. Kollias. 1997. Peyer's patch organogenesis is intact yet formation of B lymphocyte

- follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. *Proc Natl Acad Sci U S A.* 94:6319-23.
177. Le Hir, M., H. Bluethmann, M.H. Kosco-Vilbois, M. Muller, F. di Padova, M. Moore, B. Ryffel, and H.P. Eugster. 1996. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. *J Exp Med.* 183:2367-72.
178. Crook, N.E., R.J. Clem, and L.K. Miller. 1993. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. *J Virol.* 67:2168-74.
179. Liston, P., N. Roy, K. Tamai, C. Lefebvre, S. Baird, G. Cherton-Horvat, R. Farahani, M. McLean, J.E. Ikeda, A. MacKenzie, and R.G. Korneluk. 1996. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature.* 379:349-53.
180. Duckett, C.S., V.E. Nava, R.W. Gedrich, R.J. Clem, J.L. Van Dongen, M.C. Gilfillan, H. Shiels, J.M. Hardwick, and C.B. Thompson. 1996. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. *Embo J.* 15:2685-94.
181. Ambrosini, G., C. Adida, and D.C. Altieri. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med.* 3:917-21.
182. Vucic, D., H.R. Stennicke, M.T. Pisabarro, G.S. Salvesen, and V.M. Dixit. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr Biol.* 10:1359-66.
183. Kasof, G.M., and B.C. Gomes. 2000. Livin, a novel inhibitor-of-apoptosis (IAP) family member. *J Biol Chem.*
184. Chen, Z., M. Naito, S. Hori, T. Mashima, T. Yamori, and T. Tsuruo. 1999. A human IAP-family gene, apollon, expressed in human brain cancer cells. *Biochem Biophys Res Commun.* 264:847-54.
185. Deveraux, Q.L., R. Takahashi, G.S. Salvesen, and J.C. Reed. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. *Nature.* 388:300-4.
186. Roy, N., Q.L. Deveraux, R. Takahashi, G.S. Salvesen, and J.C. Reed. 1997. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. *Embo J.* 16:6914-25.
187. Takahashi, R., Q. Deveraux, I. Tamm, K. Welsh, N. Assa-Munt, G.S. Salvesen, and J.C. Reed. 1998. A single BIR domain of XIAP sufficient for inhibiting caspases. *Journal of Biological Chemistry.* 273:7787-90.

188. Tamm, I., Y. Wang, E. Sausville, D.A. Scudiero, N. Vigna, T. Oltersdorf, and J.C. Reed. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer Research*. 58:5315-20.
189. Holcik, M., C. Yeh, R.G. Korneluk, and T. Chow. 2000. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. *Oncogene*. 19:4174-7.
190. Li, F., G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, P.C. Marchisio, and D.C. Altieri. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature*. 396:580-4.
191. Skoufias, D.A., C. Mollinari, F.B. Lacroix, and R.L. Margolis. 2000. Human Survivin Is a Kinetochore-associated Passenger Protein. *J Cell Biol*. 151:1575-1582.
192. O'Connor, D.S., D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, P.C. Marchisio, and D.C. Altieri. 2000. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. *Proc Natl Acad Sci U S A*. 97:13103-7.
193. Chu, Z.L., T.A. McKinsey, L. Liu, J.J. Gentry, M.H. Malim, and D.W. Ballard. 1997. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. *Proc Natl Acad Sci U S A*. 94:10057-62.
194. Hofer-Warbinek, R., J.A. Schmid, C. Stehlik, B.R. Binder, J. Lipp, and R. de Martin. 2000. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. *J Biol Chem*. 275:22064-8.
195. Yang, Y., S. Fang, J.P. Jensen, A.M. Weissman, and J.D. Ashwell. 2000. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science*. 288:874-7.
196. Wu, G., J. Chai, T.L. Suber, J.W. Wu, C. Du, X. Wang, and Y. Shi. 2000. Structural basis of IAP recognition by Smac/DIABLO. *Nature*. 408:1008-12.
197. Liu, Z., C. Sun, E.T. Olejniczak, R.P. Meadows, S.F. Betz, T. Oost, J. Herrmann, J.C. Wu, and S.W. Fesik. 2000. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. *Nature*. 408:1004-8.
198. Adida, C., D. Berrebi, M. Peuchmaur, M. Reyes-Mugica, and D.C. Altieri. 1998. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. *Lancet*. 351:882-3.
199. Tamm, I., S.M. Kornblau, H. Segall, S. Krajewski, K. Welsh, S. Kitada, D.A. Scudiero, G. Tudor, Y.H. Qui, A. Monks, M. Andreeff, and J.C. Reed. 2000. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. *Clin Cancer Res*. 6:1796-803.

-
200. Giri, D.K., and B.B. Aggarwal. 1998. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. *J Biol Chem.* 273:14008-14.
 201. Feinman, R., J. Koury, M. Thames, B. Barlogie, J. Epstein, and D.S. Siegel. 1999. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. *Blood.* 93:3044-52.
 202. Nakshatri, H., P. Bhat-Nakshatri, D.A. Martin, R.J. Goulet, Jr., and G.W. Sledge, Jr. 1997. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. *Mol Cell Biol.* 17:3629-39.
 203. Sumitomo, M., M. Tachibana, C. Ozu, H. Asakura, M. Murai, M. Hayakawa, H. Nakamura, A. Takayanagi, and N. Shimizu. 1999. Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression. *Hum Gene Ther.* 10:37-47.
 204. Batra, R.K., D.C. Guttridge, D.A. Brenner, S.M. Dubinett, A.S. Baldwin, and R.C. Boucher. 1999. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. *Am J Respir Cell Mol Biol.* 21:238-45.
 205. Wang, C.Y., M.W. Mayo, R.G. Korneluk, D.V. Goeddel, and A.S. Baldwin, Jr. 1998. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science.* 281:1680-3.
 206. Paillard, F. 1999. Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB. *Hum Gene Ther.* 10:1-3.
 207. Liu, Z.G., H. Hsu, D.V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. *Cell.* 87:565-76.
 208. Van Antwerp, D.J., S.J. Martin, T. Kafri, D.R. Green, and I.M. Verma. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. *Science.* 274:787-9.
 209. Wang, C.Y., M.W. Mayo, and A.S. Baldwin, Jr. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. *Science.* 274:784-7.
 210. Bargou, R.C., C. Leng, D. Krappmann, F. Emmerich, M.Y. Mapara, K. Bommert, H.D. Royer, C. Scheidereit, and B. Dorken. 1996. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. *Blood.* 87:4340-7.

-
211. Krappmann, D., F. Emmerich, U. Kordes, E. Scharschmidt, B. Dorken, and C. Scheidereit. 1999. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. *Oncogene*. 18:943-53.
212. Bargou, R.C., F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, W. Arnold, H.D. Royer, E. Grinstein, A. Greiner, C. Scheidereit, and B. Dorken. 1997. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. *J Clin Invest*. 100:2961-9.
213. Schneider, E.L., Y. Mitsui, K.S. Au, and S.S. Shorr. 1977. Tissue-specific differences in cultured human diploid fibroblasts. *Exp Cell Res*. 108:1-6.
214. Ralph, P., O. Saiki, D.H. Maurer, and K. Welte. 1983. IgM and IgG secretion in human B-cell lines regulated by B-cell-inducing factors (BIF) and phorbol ester. *Immunol Lett*. 7:17-23.
215. Bargou, R.C., M.Y. Mapara, C. Zugck, P.T. Daniel, M. Pawlita, H. Dohner, and B. Dorken. 1993. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. *J Exp Med*. 177:1257-68.
216. Drexler, H.G. 1993. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. *Leuk Lymphoma*. 9:1-25.
217. Naumovski, L., P.J. Utz, S.K. Bergstrom, R. Morgan, A. Molina, J.J. Toole, B.E. Glader, P. McFall, L.M. Weiss, R. Warnke, and et al. 1989. SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. *Blood*. 74:2733-42.
218. Drexler, H.G., G. Gaedicke, M.S. Lok, V. Diehl, and J. Minowada. 1986. Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. *Leuk Res*. 10:487-500.
219. Diehl, V., H.H. Kirchner, M. Schaadt, C. Fonatsch, H. Stein, J. Gerdes, and C. Boie. 1981. Hodgkin's disease: establishment and characterization of four in vitro cell lines. *J Cancer Res Clin Oncol*. 101:111-24.
220. Wolf, J., U. Kapp, H. Bohlen, M. Kornacker, C. Schoch, B. Stahl, S. Mucke, C. von Kalle, C. Fonatsch, H.E. Schaefer, M.L. Hansmann, and V. Diehl. 1996. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. *Blood*. 87:3418-28.

-
221. Clements, G.B., G. Klein, and S. Povey. 1975. Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA. *Int J Cancer*. 16:125-33.
222. Chen, P., C. Chiu, T. Chiou, S. Maeda, H. Chiang, C. Tzeng, T. Sugiyama, and B.N. Chiang. 1984. Establishment and characterization of a human monocytoid leukemia cell line, CTV-1. *Gann*. 75:660-4.
223. Yoshie, O., T. Majima, and H. Saito. 1989. Membrane oxidative metabolism of human eosinophilic cell line EoL-1 in response to phorbol diester and formyl peptide: synergistic augmentation by interferon-gamma and tumor necrosis factor. *J Leukoc Biol*. 45:10-20.
224. Koeffler, H.P., and D.W. Golde. 1978. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. *Science*. 200:1153-4.
225. Collins, S.J., R.C. Gallo, and R.E. Gallagher. 1977. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. *Nature*. 270:347-9.
226. Asou, H., S. Tashiro, K. Hamamoto, A. Otsuji, K. Kita, and N. Kamada. 1991. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. *Blood*. 77:2031-6.
227. Nara, N., H. Kurokawa, S. Tohda, J. Tomiyama, K. Nagata, and S. Tanikawa. 1997. Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia. *Exp Hematol*. 25:199-204.
228. Champelovier, P., P. Fixe, O. Valiron, J.J. Feige, V. Praloran, and D. Seigneurin. 1997. Proliferation of LAMA-84 and LAMA-87 cell lines is modulated by autocrine loops involving M-CSF and TGF-beta. *Exp Hematol*. 25:958-65.
229. Lozzio, C.B., and B.B. Lozzio. 1975. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. *Blood*. 45:321-34.
230. Keating, A. 1987. Ph positive CML cell lines. *Baillieres Clin Haematol*. 1:1021-9.
231. Kishi, K. 1985. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. *Leuk Res*. 9:381-90.
232. Jaffrezou, J.P., T. Levade, A. Bettaieb, N. Andrieu, C. Bezombes, N. Maestre, S. Vermeersch, A. Rousse, and G. Laurent. 1996. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. *Embo J*. 15:2417-24.

233. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *J Immunol Methods*. 184:39-51.
234. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J Immunol Methods*. 139:271-9.
235. Wieder, T., C.E. Orfanos, and C.C. Geilen. 1998. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. *J Biol Chem*. 273:11025-31.
236. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*. 227:680-5.
237. Geilen, C.C., T. Wieder, and W. Reutter. 1992. Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidyltransferase in Madin-Darby canine kidney cells. *J Biol Chem*. 267:6719-24.
238. Towbin, H., T. Staehelin, and J. Gordon. 1992. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. *Biotechnology*. 24:145-9.
239. Daniel, P.T., K.T. Pun, S. Ritschel, I. Sturm, J. Holler, B. Dorken, and R. Brown. 1999. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. *Blood*. 94:1100-7.
240. Geilen, C.C., M. Bektas, T. Wieder, V. Kodolja, S. Goerdts, and C.E. Orfanos. 1997. 1 α ,25-dihydroxyvitamin D₃ induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor alpha. *J Biol Chem*. 272:8997-9001.
241. Bligh, E., and W. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol*. 37:911-917.
242. Folch, J., M. Lees, and G. Sloane. 1957. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem*. 272:497-509.
243. Reers, M., S.T. Smiley, C. Mottola-Hartshorn, A. Chen, M. Lin, and L.B. Chen. 1995. Mitochondrial membrane potential monitored by JC-1 dye. *Methods Enzymol*. 260:406-17.
244. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbour Laboratory Press, New York.

-
245. Kroczek, R.A. 1993. Southern and northern analysis. *J Chromatogr.* 618:133-45.
 246. Feinberg, A.P., and B. Vogelstein. 1984. "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. *Anal Biochem.* 137:266-7.
 247. Rath, P.C., and B.B. Aggarwal. 1999. TNF-induced signaling in apoptosis. *J Clin Immunol.* 19:350-64.
 248. Scaffidi, C., I. Schmitz, J. Zha, S.J. Korsmeyer, P.H. Krammer, and M.E. Peter. 1999. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. *J Biol Chem.* 274:22532-8.
 249. Kaufmann, S.H., and W.C. Earnshaw. 2000. Induction of apoptosis by cancer chemotherapy. *Exp Cell Res.* 256:42-9.
 250. Ghafourifar, P., S.D. Klein, O. Schucht, U. Schenk, M. Pruschy, S. Rocha, and C. Richter. 1999. Ceramide induces cytochrome c release from isolated mitochondria. Importance of mitochondrial redox state. *J Biol Chem.* 274:6080-4.
 251. Lucci, A., T.Y. Han, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot. 1999. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. *Cancer.* 86:300-11.
 252. Bose, R., M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z. Fuks, and R. Kolesnick. 1995. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. *Cell.* 82:405-14.
 253. Stehlik, C., R. de Martin, I. Kumabashiri, J.A. Schmid, B.R. Binder, and J. Lipp. 1998. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. *J Exp Med.* 188:211-6.
 254. Tamatani, M., Y.H. Che, H. Matsuzaki, S. Ogawa, H. Okado, S. Miyake, T. Mizuno, and M. Tohyama. 1999. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. *J Biol Chem.* 274:8531-8.
 255. Lee, H.H., H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng. 1999. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. *Proc Natl Acad Sci U S A.* 96:9136-41.
 256. Ameyar, M., V. Shatrov, C. Bouquet, C. Capoulade, Z. Cai, R. Stancou, C. Badie, H. Haddada, and S. Chouaib. 1999. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF-7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. *Oncogene.* 18:5464-5472.

-
257. Shatrov, V.A., M. Ameyar, C. Bouquet, Z. Cai, R. Stancou, H. Haddada, and S. Chouaib. 2000. Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state. *Int J Cancer*. 85:93-7.
258. Manna, S.K., A. Mukhopadhyay, and B.B. Aggarwal. 2000. IFN-alpha suppresses activation of nuclear transcription factors NF-kappaB and activator protein 1 and potentiates TNF-induced apoptosis. *J Immunol*. 165:4927-34.
259. Wallach, D., E.E. Varfolomeev, N.L. Malinin, Y.V. Goltsev, A.V. Kovalenko, and M.P. Boldin. 1999. Tumor necrosis factor receptor and Fas signaling mechanisms. *Annu Rev Immunol*. 17:331-67.
260. Kimura, K., C. Bowen, S. Spiegel, and E.P. Gelmann. 1999. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. *Cancer Res*. 59:1606-14.
261. Jones, B.E., C.R. Lo, H. Liu, A. Srinivasan, K. Streetz, K.L. Valentino, and M.J. Czaja. 2000. Hepatocytes sensitized to tumor necrosis factor-alpha cytotoxicity undergo apoptosis through caspase-dependent and caspase-independent pathways. *J Biol Chem*. 275:705-12.
262. Wen, Y., D.H. Yan, B. Spohn, J. Deng, S.Y. Lin, and M.C. Hung. 2000. Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. *Cancer Res*. 60:42-6.
263. Mayo, M.W., and A.S. Baldwin. 2000. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. *Biochim Biophys Acta*. 1470:M55-62.
264. Jeremias, I., C. Kupatt, B. Baumann, I. Herr, T. Wirth, and K.M. Debatin. 1998. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. *Blood*. 91:4624-31.
265. Patel, N.M., S. Nozaki, N.H. Shortle, P. Bhat-Nakshatri, T.R. Newton, S. Rice, V. Gelfanov, S.H. Boswell, R.J. Goulet, Jr., G.W. Sledge, Jr., and H. Nakshatri. 2000. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. *Oncogene*. 19:4159-69.
266. Wang, C.Y., J.C. Cusack, Jr., R. Liu, and A.S. Baldwin, Jr. 1999. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. *Nat Med*. 5:412-7.

-
267. Kasibhatla, S., L. Genestier, and D.R. Green. 1999. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. *J Biol Chem.* 274:987-92.
268. Chan, H., D.P. Bartos, and L.B. Owen-Schaub. 1999. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. *Mol Cell Biol.* 19:2098-108.
269. Tietze, M.K., T. Wuestefeld, Y. Paul, L. Zender, C. Trautwein, M.P. Manns, and S. Kubicka. 2000. IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. *Cancer Gene Ther.* 7:1315-23.
270. Huang, Y., K.R. Johnson, J.S. Norris, and W. Fan. 2000. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. *Cancer Res.* 60:4426-32.
271. Sohur, U.S., C.L. Chen, D.J. Hicks, F.E. Yull, and L.D. Kerr. 2000. Nuclear factor-kappaB/Rel is apoptogenic in cytokine withdrawal-induced programmed cell death. *Cancer Res.* 60:1202-5.
272. Ryan, K.M., M.K. Ernst, N.R. Rice, and K.H. Vousden. 2000. Role of NF-kappaB in p53-mediated programmed cell death. *Nature.* 404:892-7.
273. Lee, S.Y., D.R. Kaufman, A.L. Mora, A. Santana, M. Boothby, and Y. Choi. 1998. Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor kappaB pathways. *J Exp Med.* 188:1381-4.
274. Kimura, K., and E.P. Gelmann. 2000. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. *J Biol Chem.* 275:8610-7.
275. Gridley, D.S., M.L. Andres, and J.M. Slater. 1997. Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor. *Anticancer Res.* 17:923-8.
276. Wong, G.H., T. McHugh, R. Weber, and D.V. Goeddel. 1991. Tumor necrosis factor alpha selectively sensitizes human immunodeficiency virus-infected cells to heat and radiation. *Proc Natl Acad Sci U S A.* 88:4372-6.
277. Sasagawa, T., M. Hlaing, and T. Akaike. 2000. Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF-alpha. *Biochem Biophys Res Commun.* 272:674-80.

-
278. Pan, G., K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V.M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. *Science*. 276:1111-3.
279. Keane, M.M., S.A. Ettenberg, M.M. Nau, E.K. Russell, and S. Lipkowitz. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. *Cancer Res*. 59:734-41.
280. Mizutani, Y., O. Yoshida, T. Miki, and B. Bonavida. 1999. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. *Clin Cancer Res*. 5:2605-12.
281. Deveraux, Q.L., E. Leo, H.R. Stennicke, K. Welsh, G.S. Salvesen, and J.C. Reed. 1999. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. *Embo J*. 18:5242-51.
282. Johnson, D.E., B.R. Gastman, E. Wieckowski, G.Q. Wang, A. Amoscato, S.M. Delach, and H. Rabinowich. 2000. Inhibitor of apoptosis protein hIAP undergoes caspase-mediated cleavage during T lymphocyte apoptosis. *Cancer Res*. 60:1818-23.
283. Wang, C.Y., D.C. Guttridge, M.W. Mayo, and A.S. Baldwin, Jr. 1999. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. *Mol Cell Biol*. 19:5923-9.
284. Wu, M.X., Z. Ao, K.V. Prasad, R. Wu, and S.F. Schlossman. 1998. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. *Science*. 281:998-1001.
285. Schafer, H., A. Arlt, A. Trauzold, A. Hunermann-Jansen, and W.E. Schmidt. 1999. The putative apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22(PRG1/IEX-1) and is not expressed in vivo. *Biochem Biophys Res Commun*. 262:139-45.
286. Song, H.Y., M. Rothe, and D.V. Goeddel. 1996. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. *Proc Natl Acad Sci U S A*. 93:6721-5.
287. Arch, R.H., R.W. Gedrich, and C.B. Thompson. 2000. Translocation of TRAF proteins regulates apoptotic threshold of cells. *Biochem Biophys Res Commun*. 272:936-45.
288. Datta, R., D. Banach, H. Kojima, R.V. Talanian, E.S. Alnemri, W.W. Wong, and D.W. Kufe. 1996. Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. *Blood*. 88:1936-43.
289. McIlroy, D., H. Sakahira, R.V. Talanian, and S. Nagata. 1999. Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli. *Oncogene*. 18:4401-8.

-
290. Yoshimura, S., Y. Banno, S. Nakashima, K. Takenaka, H. Sakai, Y. Nishimura, N. Sakai, S. Shimizu, Y. Eguchi, Y. Tsujimoto, and Y. Nozawa. 1998. Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bcl-2 on ceramide formation and caspase-3 activation. *J Biol Chem.* 273:6921-7.
291. Anjum, R., A.M. Ali, Z. Begum, J. Vanaja, and A. Khar. 1998. Selective involvement of caspase-3 in ceramide induced apoptosis in AK-5 tumor cells. *FEBS Lett.* 439:81-4.
292. Li, H., L. Bergeron, V. Cryns, M.S. Pasternack, H. Zhu, L. Shi, A. Greenberg, and J. Yuan. 1997. Activation of caspase-2 in apoptosis. *J Biol Chem.* 272:21010-7.
293. Martin, D.A., R.M. Siegel, L. Zheng, and M.J. Lenardo. 1998. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. *J Biol Chem.* 273:4345-9.
294. Wieder, T., F. Essmann, A. Prokop, K. Schmelz, K. Schulze-Osthoff, R. Beyaert, B. Dorken, and P.T. Daniel. 2001. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. *Blood.* 97:1378-87.
295. Fulda, S., G. Strauss, E. Meyer, and K.M. Debatin. 2000. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. *Blood.* 95:301-8.
296. Teitz, T., T. Wei, M.B. Valentine, E.F. Vanin, J. Grenet, V.A. Valentine, F.G. Behm, A.T. Look, J.M. Lahti, and V.J. Kidd. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. *Nat Med.* 6:529-35.
297. Sun, X.M., M. MacFarlane, J. Zhuang, B.B. Wolf, D.R. Green, and G.M. Cohen. 1999. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. *J Biol Chem.* 274:5053-60.
298. Wesselborg, S., I.H. Engels, E. Rossmann, M. Los, and K. Schulze-Osthoff. 1999. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. *Blood.* 93:3053-63.
299. Boesen-de Cock, J.G., A.D. Tepper, E. de Vries, W.J. van Blitterswijk, and J. Borst. 1999. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. *J Biol Chem.* 274:14255-61.
300. Kataoka, T., M. Schroter, M. Hahne, P. Schneider, M. Irmeler, M. Thome, C.J. Froelich, and J. Tschopp. 1998. FLIP prevents apoptosis induced by death receptors but not by

- perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. *J Immunol.* 161:3936-42.
301. Wallach, D., M. Boldin, E. Varfolomeev, R. Beyaert, P. Vandenabeele, and W. Fiers. 1997. Cell death induction by receptors of the TNF family: towards a molecular understanding. *FEBS Lett.* 410:96-106.
302. Khwaja, A., and L. Tatton. 1999. Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway. *J Biol Chem.* 274:36817-23.
303. Luschen, S., S. Ussat, G. Scherer, D. Kabelitz, and S. Adam-Klages. 2000. Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression. *J Biol Chem.* 275:24670-8.
304. Sawada, M., S. Nakashima, Y. Banno, H. Yamakawa, K. Takenaka, J. Shinoda, Y. Nishimura, N. Sakai, and Y. Nozawa. 2000. Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells. *Oncogene.* 19:3508-20.
305. Perkins, C.L., G. Fang, C.N. Kim, and K.N. Bhalla. 2000. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. *Cancer Res.* 60:1645-53.
306. Robertson, J.D., V. Gogvadze, B. Zhivotovsky, and S. Orrenius. 2000. Distinct pathways for stimulation of cytochrome c release by etoposide. *J Biol Chem.* 275:32438-43.
307. Chen, Q., B. Gong, and A. Almasan. 2000. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. *Cell Death Differ.* 7:227-33.
308. Bradham, C.A., T. Qian, K. Streetz, C. Trautwein, D.A. Brenner, and J.J. Lemasters. 1998. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. *Mol Cell Biol.* 18:6353-64.
309. Tafani, M., T.G. Schneider, J.G. Pastorino, and J.L. Farber. 2000. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. *Am J Pathol.* 156:2111-21.
310. Johnson, B.W., E. Cepero, and L.H. Boise. 2000. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. *J Biol Chem.* 275:31546-53.

-
311. Slee, E.A., S.A. Keogh, and S.J. Martin. 2000. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. *Cell Death Differ.* 7:556-65.
312. Chmura, S.J., E. Nodzenski, M.A. Beckett, D.W. Kufe, J. Quintans, and R.R. Weichselbaum. 1997. Loss of ceramide production confers resistance to radiation-induced apoptosis. *Cancer Research.* 57:1270-1275.
313. Pierce, R.H., J.S. Campbell, A.B. Stephenson, C.C. Franklin, M. Chaisson, M. Poot, T.J. Kavanagh, P.S. Rabinovitch, and N. Fausto. 2000. Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. *Am J Pathol.* 157:221-36.
314. Schulze-Osthoff, K., A.C. Bakker, B. Vanhaesebroeck, R. Beyaert, W.A. Jacob, and W. Fiers. 1992. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. *J Biol Chem.* 267:5317-23.
315. Goossens, V., J. Grooten, K. De Vos, and W. Fiers. 1995. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. *Proc Natl Acad Sci U S A.* 92:8115-9.
316. Schulze-Osthoff, K., R. Beyaert, V. Vandevorde, G. Haegeman, and W. Fiers. 1993. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. *Embo J.* 12:3095-104.
317. Sanchez-Alcazar, J.A., E. Schneider, M.A. Martinez, P. Carmona, I. Hernandez-Munoz, E. Siles, P. De La Torre, J. Ruiz-Cabello, I. Garcia, and J.A. Solis-Herruzo. 2000. Tumor necrosis factor-alpha increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. *J Biol Chem.* 275:13353-61.
318. Gottlieb, E., M.G. Vander Heiden, and C.B. Thompson. 2000. Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. *Mol Cell Biol.* 20:5680-9.
319. Khwaja, A., and L. Taton. 1999. Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway. *Journal of Biological Chemistry.* 51:36817-36823.

-
320. Friesen, C., S. Fulda, and K.M. Debatin. 1999. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. *Cell Death Differ.* 6:471-80.
321. Quillet-Mary, A., J.P. Jaffrezou, V. Mansat, C. Bordier, J. Naval, and G. Laurent. 1997. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. *J Biol Chem.* 272:21388-95.
322. Lee, S.Y., A. Reichlin, A. Santana, K.A. Sokol, M.C. Nussenzweig, and Y. Choi. 1997. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. *Immunity.* 7:703-13.
323. Ichijo, H., E. Nishida, K. Irie, P. ten Dijke, M. Saitoh, T. Moriguchi, M. Takagi, K. Matsumoto, K. Miyazono, and Y. Gotoh. 1997. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science.* 275:90-4.
324. Roulston, A., C. Reinhard, P. Amiri, and L.T. Williams. 1998. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. *J Biol Chem.* 273:10232-9.
325. Assefa, Z., A. Vantieghem, M. Garmyn, W. Declercq, P. Vandenabeele, J.R. Vandenheede, R. Bouillon, W. Merlevede, and P. Agostinis. 2000. p38 mitogen-activated protein kinase regulates a novel, caspase-independent pathway for the mitochondrial cytochrome c release in ultraviolet B radiation-induced apoptosis. *J Biol Chem.* 275:21416-21.
326. Wilson, J., E. Braunwald, K. Isselbacher, R. Petersdorf, J. Martin, A. Fauci, and R. Root. 1991. Principles of internal medicine. *McGraw-Hill.* 12th edition.